Abstract | The immune system is routinely exposed to dead cells during normal cell turnover, injury and infection. Mechanisms must exist to discriminate between different forms of cell death to correctly eliminate pathogens and promote healing while avoiding responses to self, which can result in autoimmunity. However, an effective immune response against host tissue is often needed to eliminate tumours following treatment with chemotherapeutic agents that trigger tumour cell death. Consequently, a central problem in immunology is to understand how the immune system determines whether cell death is immunogenic, tolerogenic or 'silent'.
One of the most primitive host defences against intracellular infection in animals is for the host cell to die preemptively before the parasite can replicate and kill the cell en route to further infection. It is therefore not surprising that in the vertebrate immune system cell death triggers both innate and adaptive immune responses. However, cell death does not only occur during infection; in humans it is estimated that one million cells die per second in the course of normal tissue turnover 1 , and in most cases this does not result in autoreactivity. So, how does the immune system discriminate between different types of cell death? Historically, this question has been addressed by using two general approaches: by investigating the signals that are produced by dying cells and by investigating the consequences of different forms of cell death.
The first approach is based on the theory that the recognition of pathogen-associated molecular patterns (PAMPs), such as bacterial cell wall components or viral RNA, by immune cells dictates the difference between 'silent' cell death (which occurs in the absence of a pathogen) and immunogenic cell death (which is induced by a pathogen) 2 . However, the presence or absence of PAMPs cannot be the only criterion that determines immunogenicity because transformed cells, which generally are not infected by foreign organisms, frequently elicit highly effective antitumour immune responses as they die 3 . In addition, debris from non-transformed cells in some settings can stimulate organ-specific or general autoimmune responses 4 . Consequently, the concept of damageassociated molecular patterns (DAMPs; see BOX 1) has been proposed to explain the potential immunogenicity of stressed or dying uninfected cells 5 . DAMPs are released from dying cells and induce immune responses to cellular antigens regardless of whether the cell is a tumour cell, is derived from normal tissue or is infected with a pathogen. Therefore, it has been proposed that for cell death to be immunogenic, it must release DAMPs to stimulate immune cells.
The second approach is based on the theory that distinct types of cell death (BOX 2) induce different types of immune response. Specifically, physiological cell death (apoptosis; see BOX 2) is thought to be intrinsically tolerogenic, whereas pathological cell death (necrosis) is inherently immunogenic and elicits inflammatory reactions 6 . However, in-depth investigations have shown that cells dying by apoptosis can be highly immunogenic, whereas necrotic cells can be less immunogenic than cells undergoing an immunogenic form of apoptosis 3, 7 . In an effort to reconcile these different data, it has been proposed that there are subtypes of cell death, such as immunogenic and non-immunogenic apoptosis, and that subtle differences in the composition of the cell surface and/or in the products that are secreted by the dying cells (which could include DAMPs) determine whether the death of the cell is immunogenic or not 8 . In animals, cell fate is another important parameter in the immune response to dead cells. Dead cells are either shed from bodily surfaces (such as the skin or mucosa) or they are cleared through engulfment by other cells. Those that are shed have little or no influence on the host immune response but those that are engulfed have the potential to affect it. This is particularly true when dying or dead cells are engulfed by antigen-presenting cells, such as dendritic cells (DCs) . DCs can direct the immune response by presenting antigens that are associated with dying cells to T cells. Whether or not this occurs depends on several factors, including the antigen, the DAMPs derived from the dying cell and the type of DC that engulfs the dead cell.
Damage-associated molecular pattern (DAMP) . A molecule that is released from the degraded stroma (for example, hyaluronate), nucleus (for example, high-mobility group box 1 protein) and the cytoplasm (for example, ATP, uric acid, S100 calcium-binding proteins and heat shock proteins) as a result of cellular stress, cellular damage and non-physiological cell death. DAMPs are thought to elicit local inflammatory reactions.
Dendritic cell
The main antigen-presenting cell of the immune system. Engulfment of dying cells by dendritic cells can lead to tolerance or immune responses to associated antigens.
Delayed-type hypersensitivity
A cellular immune response to antigen that develops over 24−72 hours, is associated with the infiltration of T cells and monocytes and is dependent on the production of T helper 1-type cytokines.
Tolerance
A term that denotes lymphocyte non-responsiveness to antigen, but implies an active process, not simply a passive lack of response.
Therefore, the nature of the immune response to cell death depends on the following considerations: which cell dies, where it dies, how it dies, which cell eats it and when (or if) associated antigens have been or will be recognized. variations in these factors can have consequences that range from effective anti-pathogen or antitumour immune responses to autoimmune pathology.
In this Review, we discuss whether the immune response to cell death results in a measurable immune response (such as antitumour immune responses, delayed-type hypersensitivity, antibody responses or autoimmunity), in immune tolerance or in no response. These different responses are linked, and the consequences of exposure to dying cells for every aspect of each immune response are not fully understood. Although our challenge is to view the complete picture, we provide here only a snapshot of this rapidly evolving field.
Dying cells affect immune responses
The inaugural description of apoptosis as a form of cell death that is distinct from necrosis (see BOX 2) proposed that apoptosis was immunologically silent, whereas necrosis stimulated an immune response 9 . More than two decades later, a form of immune tolerance was linked to the engulfment of apoptotic cells; cells that were chemically modified with an antigenic hapten induced a state of tolerance when injected into the anterior chamber of the eye provided that they underwent apoptosis at this site 10 . In addition, inflammatory cells responding to a viral infection in the eye also underwent apoptosis and induced systemic tolerance to viral antigens 10 . Subsequent studies generalized these findings to show that apoptotic cells that are engulfed by DCs can produce a state of antigenic tolerance in models of contact hypersensitivity 11 , autoimmunity [12] [13] [14] and other immune responses [15] [16] [17] .
The induction of immune tolerance by apoptotic cells in vivo has been proposed to explain additional phenomena. Intravenous injection of spleen cells that had been coupled to a hapten could induce tolerance in a model of contact hypersensitivity to the hapten 18, 19 through a mechanism that involved apoptosis of the injected cells mediated by the interaction between CD95 (also known as FAS) and its ligand, CD95L (also known as FASl) 11 . In addition, graft tolerance induced by the intravenous injection of allogeneic spleen cells [20] [21] [22] , as well as the tolerance-inducing ability of antigens associated with ultraviolet-irradiated skin, have been shown to involve the induction of apoptosis and the engulfment of apoptotic cells by the immune system 23, 24 . These and related findings promoted the simple idea that apoptosis is tolerogenic or non-immunogenic and necrosis is immunogenic.
However, this idea has been successfully challenged by various observations showing that certain subtypes of apoptosis can be immunogenic. For example, the apoptosis of tumour cells induced by chemotherapy was shown to prime an immune response 7 . Apoptosis was the key event in this study, as priming depended on the activation of caspases (see below). In addition, other studies have shown that antigens from apoptotic cells can be effectively cross-presented to cytotoxic T cells (CTls) and prime an immune response 25, 26 . Therefore, whether a cell undergoes necrosis or apoptosis does not predict whether the outcome will be an immune response or tolerance.
Immunogenic cell death using several experimental systems
, it has become clear that various factors work in concert to determine whether cell death is immunogenic or not. These parameters include the intrinsic antigenicity of the cells, the history of activation or stress before cell death, the nature of the cell death inducer, the precise cell death pathway that is engaged and the availability of immune cells that can respond.
Cell type, activation state and stress. During oncogenesis, tumours can acquire many mutations, some of which give rise to altered antigenic peptides that might be recognized by the immune system as altered self 27 . Consequently, during radiotherapy or chemotherapy in which the tumour cells are induced to die, immune responses can be biased towards a response against the tumour (altered self) antigens rather than normal self antigens, to which the immune system has been tolerized 8, 28, 29 . In addition, the activation state of the cell before the induction of cell death can affect its immunogenicity. Activated, but not resting, γ-irradiated peripheral blood mononuclear cells can induce the expression of maturation markers (such as CD80, CD83 and CD86) and the secretion of pro-inflammatory cytokines by DCs in vitro 30 . This suggests that activated apoptotic cells may possess endogenous adjuvant properties. At present, the molecular nature of this activation-dependent immune stimulation is unknown. An interesting contrast is with the effect of T cells that succumb to activation-induced cell death after clonal expansion; these cells promote
Box 1 | Damage-associated molecular patterns
Potential immunogenic signals that originate from dying cells include proteins that appear on the surface of stressed and dying cells, such as calreticulin and heat shock proteins (HSPs), lipid moieties that flip from the inner plasma membrane leaflet to the outer leaflet, such as phosphatidylserine 39, 61 , and proteins, nucleic acids and their degradation products that are released by dying cells, such as high-mobility group box 1 protein (HMGB1) 52 , oligonucleotides, polynucleotides, nucleosides and urate [44] [45] [46] 106 . These damage-associated molecular patterns (DAMPs) are released from or exposed on the surface of dying cells and determine apoptotic cell engulfment, dendritic cell (DC) activation, antigen processing, DC maturation and T cell activation. Pattern recognition receptors (PRRs) that are expressed by DCs and recognize some of these DAMPs include endocytic receptors that stimulate antigen uptake, such as scavenger and C-type lectin receptors 107 . Other PRRs that are present on or in DCs and stimulate the post-uptake reactions include Toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors and retinoic acid-inducible gene I (RIG-I)-like helicases 53, 108 . One single molecular entity that is exposed or released by dying tumour cells might act on multiple PRRs. Therefore, HMGB1, for example, can act on receptor for advanced glycosylation end products (RAGE) and possibly TLRs, including TLR2 and TLR4 (rEfS 52,53), although whether it acts on TLR4 is controversial 54 . Similarly, HSPs exposed on or released by tumour cells can act on many receptors, including CD91, scavenger receptors, TLR2 and TLR4 (rEf. 53) .
Polynucleotides and oligonucleotides that are derived from degraded DNA or RNA can act on TLR3, TLR7, TLR8 or TLR9, as well as on intracellular receptors, including RIG-I, MDA5 or LGP2 (also known as DHX58), whereas ATP and its degradation products can activate or inhibit distinct classes of purinergic receptors 46, 109, 110 .
Hapten
A molecule that can bind antibody but cannot by itself elicit an immune response. Antibodies that are specific for a hapten can be generated when the hapten is chemically linked to a protein carrier that can elicit a T cell response.
Contact hypersensitivity
A form of delayed-type hypersensitivity (type IV), in which T cells respond to antigens that are introduced through skin contact. This step requires dendritic cell mobilization from the skin to the draining lymph nodes to prime the antigen-specific T cells.
CD95L
An apoptosis-inducing or death ligand of the tumour necrosis factor family.
Caspase
An enzyme belonging to a family of cytoplasmic proteases that cleave their substrate after an aspartic acid residue. Initiator caspases are typically activated in response to particular stimuli. Effector caspases are activated by initiator caspases and are particularly important for the ordered dismantling of vital cellular structures.
Cross-present
The presentation of exogenous antigen to CD8 + T cells by antigen-presenting cells (APCs). The antigen must be taken up by APCs and then re-routed to the MHC class I pathway of antigen presentation, resulting in the initiation of a CD8 + T cell response to an antigen that is not present within APCs. tolerance by stimulating regulatory CD8 + T cells 31 . Thus, the timing of uptake of dead cells can be important: cells that die at the peak of an immune response can be immunogenic, whereas cells that die as the immune response wanes can be tolerogenic.
Activation-induced cell death
Stress responses such as the DNA damage response can change the composition of the cellular proteome at several levels. DNA damage of transformed cells induces the expression of surface proteins such as natural killer group 2, member D (NKG2D) ligands, which act on NKG2D expressed by NK cells and CTls 32 . Furthermore, DNA damage or activation of oncogenes can induce cell senescence through a pathway that relies in part on the secretion of pro-inflammatory cytokines, such as insulin-like growth factor-binding protein 7 (IGFBP7) 33 and interleukin-6 (Il-6) 34 , on the production of CXC-chemokine ligand 8 (CXCl8; also known as Il-8) and other chemokines 34, 35 , and on the expression of CXC-chemokine receptor 2 (CXCR2; also known as Il-8RB) 35 . Although the impact of these mediators on the antitumour immune response has not been individually evaluated, it is possible that they may condition the local immune response once senescent tumour cells begin to die. Indeed, the induction of senescence by the expression of a p53 transgene in hepatocellular carcinomas can stimulate a vigorous antitumour immune response that is mediated by innate immune cells and is necessary for subsequent tumour clearance 36 . Together, these examples illustrate that the history of a cell, including its mode of activation and manner of stress, and the type of cell that dies, can determine whether or not cell death is immunogenic.
Characteristics of dying cells. Treatment with a specific set of chemotherapeutic agents can induce the exposure of heat shock proteins (HSPs) on the cell surface (fIG. 1).
It has been suggested that such chaperones can capture cellular antigens (including tumour antigens) and facilitate their presentation following uptake by DCs 37 . Alternatively, the chaperones might be involved in the physical or functional interaction between the membrane of dying cells and that of the engulfing DC 38, 39 . For example, dying myeloma cells expose the chaperone HSP90 on their surface, and this may facilitate their recognition by DCs 39 . Similarly, in response to some chemotherapeutic agents (such as anthracyclins), but not others (such as mitomycin C or etoposide), tumour cells expose complexes that are formed by the chaperone calreticulin and the disulphide isomerase eRp57 (also known as PDIA3) on their cell surface. This occurs at a preapoptotic stage and facilitates the uptake of dying cells by DCs 8, 40 . exposure of these complexes strongly correlates with immunogenicity, and anthracyclin-treated dying tumour cells that expose calreticulin can be used to vaccinate against cancer; these dying tumour cells lose their immunogenicity following small interfering
Box 2 | Types of cell death
The current nomenclature uses several terms to define morphologically distinct types of cell death 57, 111 : Apoptosis Apoptosis is accompanied by rounding-up of the cell, retraction of pseudopods, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), few or no ultrastructural modifications of cytoplasmic organelles and plasma membrane blebbing, but cell integrity is maintained until the final stages of the process. There are several distinct subtypes of apoptosis that, although morphologically similar, can be triggered by different biochemical routes -for example, through the intrinsic or the extrinsic pathway or with or without caspase activation. Furthermore, the apparent uniformity of apoptotic cell death can conceal differences in the functional outcomes of this process, including whether or not dying apoptotic cells are recognized by the immune system 57 .
Autophagic cell death
Autophagic cell death occurs in the absence of chromatin condensation but is accompanied by massive autophagic vacuolization of the cytoplasm. Although the term autophagic cell death suggests that cell death is executed by autophagy, the term simply describes cell death that occurs alongside autophagy. In this sense, the term autophagic cell death is a misnomer 62 . necrosis Necrosis is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents. Necrosis has traditionally been considered merely as an accidental, uncontrolled form of cell death that occurs only in pathological circumstances. Nonetheless, evidence is accumulating to suggest that the execution of necrotic cell death may be subtly regulated by a set of signal transduction pathways and catabolic mechanisms 112, 113 .
Secondary necrosis
Secondary necrosis is the dissolution of the cell following apoptosis. It is difficult to distinguish from conventional necrosis based on morphology, but the consequences of apoptosis for the immune response are recognizable.
Pyroptosis
Pyroptosis involves the crucial contribution of a particular set of caspase 1-activating complexes, known as the inflammasomes. Although the molecular circuitry of pyroptosis (which is often induced by intracellular bacteria) has been investigated in vitro 108 , no data are available on the immunogenicity of pyroptosis in vivo.
mitotic catastrophe
Mitotic catastrophe leads to cell death during or after mitosis and is morphologically discernible by multinucleation or micronucleation and/or mitotic arrest before the cells adopt the morphology of an apoptotic or necrotic cell 114 .
NKG2D
A lectin-type activating receptor that is expressed on the surface of natural killer (NK), NKT, γδ T cells and some cytolytic CD8 + αβ T cells. NKG2D recognizes the ligands MHC class Ipolypeptide-related sequence A (MICA) and MICB in humans and retinoic acid early transcript 1 (rAE1) and H60 in mice. Such ligands are generally expressed by infected, stressed or transformed cells.
Senescence
A nearly irreversible stage of permanent G 1 cell cycle arrest, linked to morphological changes (flattening of the cells), metabolic changes and changes in gene expression, the induction of which depends on p53 and cell cycle blockers such as p21 and p16.
p53
An important transcription factor that is activated by numerous genotoxic insults to induce cell cycle arrest, cell senescence or apoptosis. p53 is frequently mutated or functionally inactivated in cancer.
RNA-mediated depletion or antibody-mediated neutralization of calreticulin. Conversely, cells that succumb to non-immunogenic cell death in response to, for example, mitomycin C or etoposide can be rendered immunogenic by binding of recombinant calreticulin to their cell surface 8 . However, the binding of recombinant calreticulin to live tumour cells is not sufficient to render them immunogenic 8 , meaning that additional factors are essential for immunogenicity.
For engulfment to occur, dying cells can emit 'find me' signals that attract professional phagocytes and thereby accelerate their removal (BOX 4) . One such signal is lysophosphatidylcholine, the release of which is mediated by the breakdown of the membrane glycerolipid phosphatidylcholine (a normal membrane constituent) by calcium-independent phospholipase A2 (iPlA2; also known as PlA2G6) 41 . Although the requirement for lysophosphatidylcholine release for immunogenic cell death has not been determined, autoimmunity has been observed in mice in which phagocytes lack the G protein-coupled receptor G2A (also known as GPR132) 42 , which is required for the response to lysophosphatidylcholine 43 . It is therefore possible that such find me signals are more important for the induction of tolerance than for the initiation of an immune response. By contrast, other signals, such as the release of nucleotides (including ATP and uTP) from damaged neurons in mice, are thought to attract microglial cells (macrophage-like phagocytes in the brain) to sites of tissue damage 44 . Indeed, ATP, which is released from dying cells and activates macrophages 45 , may also be required for the immunogenicity of dying tumour cells (l.Z. and G.K., unpublished observations). Nucleotide products, such as uric acid, can also function as DAMPs, presumably by activating the inflammasome in antigenpresenting cells, thereby stimulating the production of inflammatory cytokines such as Il-1β, Il-18 and Il-33, the secretion of which depends on the inflammasomemediated activation of caspase 1 (rEfS 46, 47) . Whether any of these cytokines are required for the immune response against dying cells is an issue of ongoing investigation.
Following permeabilization of the plasma membrane, cells can release several proteins including DAMPs that alert the immune system
. One such DAMP is the nuclear DNA-binding protein highmobility group box 1 protein (HMGB1) 48 . Although it was initially thought that HMGB1 is released from the nucleus only during primary necrosis, recent data indicate that HMGB1 can also be released during secondary necrosis (BOX1) that occurs following apoptosis 28, [49] [50] [51] . It seems that HMGB1 can bind several pattern recognition receptors (PRRs), including Toll-like receptor 2 (TlR2), TlR4 and RAGe (receptor for advanced glycosylation end products; also known as AGeR) 52, 53 . Caution is of course warranted when interpreting the role of TlRs in these studies, as the possible contamination with TlR ligands is always an issue. When in a complex with CpG-containing DNA, HMGB1 can also induce the synergistic interaction and activation of RAGe and TlR9 (rEf. 54) . Depletion of HMGB1 from tumour cells undergoing immunogenic apoptosis (induced by anthracyclins, oxaliplatin or ionizing irradiation) abolishes their ability to induce T cell priming or to protect mice against tumour growth following vaccination 28 . This indicates that HMGB1 is required for the immunogenicity of cell death (fIG. 1) .
A recent study has identified SIN3A-associated protein 130 (SAP130), which is a component of small nuclear ribonucleoprotein, as another DAMP that is released by necrotic and late apoptotic cells 55 . SAP130 specifically binds to macrophage-inducible C-type lectin (MINCle; also known as CleC4e), which is an immunoreceptor tyrosine-based activation motif (ITAM)-coupled activating receptor that is mainly expressed by macrophages. Neutralization of MINCle with a specific antibody inhibited the recruitment of neutrophils and the production of pro-inflammatory cytokines following intraperitoneal injection of dead tumour cells 55 , indicating a role for the SAP130-MINCle interaction in the immunogenicity of dead cells in vivo. However, the expression and function of MINCle by DCs has yet to be directly examined.
Dying cells also expose or release another as yet unidentified DAMP that is recognized by the receptor C-type lectin domain family 9, member A (CleC9A), which is expressed by CD8α + DCs
56
. This activates spleen tyrosine kinase (SyK) and results in cross-presentation of associated antigens on MHC class I molecules. As discussed in the next section, such cross-presentation is important not only for the induction of immune responses by dying cells, but also for the induction of tolerance. Therefore, identification of the CleC9A ligand will be a valuable advancement in our understanding of the immunological consequences of cell death.
Box 3 | Assays for determining immunogenic and tolerogenic cell death
In one widely used assay, cancer cells are treated in vitro to programme them for cell death and are subcutaneously injected into one flank of a mouse. One week later, live tumour cells are injected subcutaneously into the opposite flank, and tumour growth is monitored. The absence of cancer development is interpreted as the sign of antitumour immunity. In this experimental set-up, cytotoxic T lymphocyte (CTL)
Delayed-type hypersensitivity (DTH) response is assessed 24 hours later by quantifying antigen-specific footpad swelling. This assay can also be adapted for the assessment of immune tolerance. In this case, apoptotic cells are coupled with antigen or administered to DCs along with antigen and then injected intravenously into mice. The mice are immunized two days later by subcutaneous injection of the antigen. Four days later the mice are injected with the same antigen in one footpad and a control solution in the opposite footpad. DTH response is assessed 24 hours later by measuring the difference in footpad swelling between the antigen-injected and control footpad. Nature Reviews | Immunology 
HMGB1
A DAMP that is released from dying cells. It can be modified by reactive oxygen species to alter its immunostimulatory effects.
Macroautophagy
The largely non-specific autophagic sequestration of cytoplasm into a double-or multiple-membrane-delimited compartment (an autophagosome) of non-lysosomal origin. Certain proteins, organelles and pathogens may be selectively degraded by macroautophagy.
Caspase activation. The activation of caspases has many effects on the immunogenicity of cell death 57 ; for example, caspase activity can lead to the proteolytic destruction of immunodominant epitopes 58 . Conversely, caspase activation can reveal new epitopes by mobilizing long-lived proteins that are stably anchored on the cytoskeleton and by facilitating their access to the cross-presentation pathway in DCs 59 . In addition, cleavage of antigens by caspases can create new amino termini that target the antigens for proteasomal degradation 60 , which could facilitate cross-presentation of the resulting peptides. Such caspase-enhanced presentation could be important for the pathogenesis of HIv-1 because a high frequency of effector CD8 + T cells that recognize caspase-cleaved epitopes can be found in the peripheral blood of individuals infected with HIv-1 (rEf. 59); the frequency of these effector CD8 + T cells correlates with the frequency of apoptotic CD4 + T cells. The inhibition of caspases affects the exposure of find me signals 41 , 'eat me' signals 41 (BOX 4) and the secretion of DAMPs 52 from dying cells, as well as the exposure of calreticulin on the surface of anthracyclintreated cancer cells 61 . Indeed, subcutaneous administration of the chemical caspase inhibitor Z-vAD-FMK or transfection with a caspase inhibitor (such as baculovirus p35) were shown to destroy the ability of anthracyclin-treated cancer cells to induce antitumour immune responses 7 .
Autophagy. Macroautophagy (also known as autophagy) is an important catabolic mechanism for the sequestration and lysosomal degradation of cytoplasmic material. Although autophagy may not be an effector mechanism of cell death 62 , it often accompanies cell death 63 
.
Autophagy has been shown to be required for the generation of the find me signal lysophosphatidylcholine and the eat me signal that is generated by phosphatidylserine exposure 64 
. Therefore, a failure in autophagy blocks the removal of apoptotic cells and influences the immunogenicity of cell death. Autophagy might also stimulate the release of HMGB1 (rEf. 65 ), suggesting another link between autophagy and the immune response to cell death.
In one model of immunogenic cell death, influenza virus-infected mouse embryonic fibroblasts that are deficient for the pro-apoptotic molecules BCl-2-associated X protein (BAX) and BCl-2 antagonist/ killer (BAK; also known as BAK1), and therefore cannot engage apoptosis through the mitochondrial pathway, were induced to undergo non-apoptotic cell death accompanied by high levels of autophagy 66 . These DNA-damaged Bax -/-
Bak
-/-cells were found to be more efficient at facilitating the cross-priming of antigenspecific CD8 + T cells following their adoptive transfer to wild-type mice compared with wild-type cells undergoing apoptosis 67 . This gain of immunogenicity was lost following inhibition of the expression of the essential When cells succumb to the immunogenic variant of apoptosis, they expose calreticulin on the cell surface. In addition, they might expose or release other chaperone proteins, including members of the heat shock protein (HSP) family, such as HSP70 and HSP90. These factors can facilitate the uptake of the dying cells. Dying cells also release the damage-associated molecular pattern high-mobility group box 1 protein (HMGB1), which is recognized by dendritic cells (DCs) through RAGE (receptor for advanced glycosylation end products), Toll-like receptor 2 (TLR2) or TLR4. HMGB1 has been shown to be required for cell death to be immunogenic. Surface-exposed molecules such as calreticulin, HSP70 and HSP90, as well as soluble products from dying cells, affect the function of DCs by binding to specific receptors such as CD91 (not shown), which recognizes bridging molecules for 'eat me' signals
, and other TLRs and pattern recognition receptors (PRRs) (not shown). These DCs can then prime CD4 + and CD8 + T cells and thereby trigger immunogenic T helper 1 (T H 1) cell and cytotoxic T lymphocyte (CTL) responses, respectively. C-type lectin domain family 9, member A (CLEC9A) has recently been shown to couple the recognition of necrotic cells to the subsequent cross-presentation of antigen to CTLs; however, its ligand has yet to be described. TCR, T cell receptor.
Immune-privileged site
An area in the body that has a decreased but not absent immune response to foreign antigens, including tissue grafts. These sites include the brain, eye, testis and placenta.
'Helpless' CTL
A CD8 + T cell that has undergone activation without additional stimulation ('help') by CD4 + T cells.
autophagy protein ATG5 (autophagy-related protein 5).
Although the exact mechanisms that account for the immunogenic effect of autophagy remain unclear, these results highlight the importance of catabolic processes in shaping the immune response.
So, several factors influence the effect of dying cells on an immune response. If the dying cells are not immunogenic, they can be tolerogenic or have no effect on the immune response. These ideas are discussed in the following section.
Tolerance induction by dying cells
Although dying cells can promote an effective immune response, we know that under some conditions they can induce immune tolerance. Consequently, the key to understanding this 'immuno-logical' decision is to examine the mechanisms of tolerance induction by dying cells and then relate them to the mechanisms of immunogenicity discussed above. Ideally, immunogenic cell death should be directed towards tumour cells and infected cells, whereas tolerogenic cell death should be associated with preventing unwanted immune responses to self (for example, during autoimmunity) or the protection of organs in which excessive inflammation can result in irreversible organ damage (for example, in immune-privileged sites such as the eye) 10 . Studies of immune tolerance induced by dying cells have used experimental systems such as those described in BOX 3. These studies have identified factors that are important for tolerogenic cell death, which are outline below.
The availability of help. Antigens that are associated with apoptotic cells and engulfed by DCs can be crosspresented by MHC class I molecules to CD8 + T cells to prime CTls 68 . Perhaps paradoxically, the induction of tolerance by apoptotic cells depends on MHC class I molecules and involves immune suppression by CD8 + T cells 11, 25, 26 . Reconciling cross-presentation and 'crosstolerance' provides insights into one mechanism of immune tolerance induction by dying cells.
Following antigen recognition by CD8 + T cells and their development into CTls, the long-term fate of these cells is determined by additional signals that are provided by DCs, which must be 'licensed' by a previous CD40-CD40 ligand (CD40l)-mediated interaction with activated CD4 + T cells 69 . Without this additional signal, the activated 'helpless' CTLs function as primary effector T cells but with a short lifespan 70 or die as a result of activation-induced cell death following subsequent exposure to antigen 71, 72 . Activation-induced cell death is mediated by the expression of the death ligand TRAIl (TNF-related apoptosis-inducing ligand; also known as TNFSF10), which triggers apoptosis in helpless CTls and other activated T cells 71, 73 . The relationship between these observations and the induction of tolerance by apoptotic cells became clear in a recent series of experiments 73 . Specifically, DCs that had engulfed necrotic cells were shown to present antigen to both CD4 + and CD8 + T cells, but those that engulfed apoptotic cells presented antigen to CD8 + T cells but not CD4 + T cells. As a result, the CD8 + T cells produced TRAIl following re-exposure to the
Box 4 | Engulfment of dying cells
Three classes of events accompany cell death to promote engulfment 90, 115 . First, the cell releases soluble 'find me' signals, producing a gradient that attracts phagocytic cells. One such signal is lysophosphatidylcholine 41 , which is produced by the action of calcium-independent phospholipase A2 (iPLA2). Caspases cleave and thereby activate iPLA2, although this is not required for the production of the lipid signal. Another such signal is the secretion of CX 3 C-chemokine ligand 1 (CX 3 CL1), which recruits phagocytes 116 and induces the expression of the bridging molecule MFGE8 (milk fat globule EGF factor 8 protein), resulting in the detection of apoptotic cells 117 . Many cells express a 'don't eat me' signal, such as CD31 (rEf. 118) or CD47 (rEf. 119) , which must be removed for phagocytosis to occur. However, how the signals that are provided by these molecules are negated for cell death to occur remains unexplored.
As cells die, they expose 'eat me' signals. These include oxidized lipids, changes in carbohydrate composition and phosphatidylserine. Loss of ATP or permeabilization of the plasma membrane results in diffusion of phosphatidylserine and other asymmetrically oriented phospholipids to both membrane leaflets. During apoptosis, or in response to other signals such as calcium flux, a more rapid 'scrambling' of membrane phospholipids occurs, resulting in loss of phospholipid asymmetry; this includes the appearance of phosphatidylserine on the outer leaflet. To date, the caspase-dependent mechanisms that are responsible for phospholipid scrambling have been elusive. Nevertheless, detection of apoptosis using the phosphatidylserine probe annexin V 120 is a useful marker when paired with agents to detect loss of plasma membrane integrity.
Although a receptor for phosphatidylserine on phagocytes has been described, this molecule is now known to be a nuclear factor 121 and therefore is unlikely to directly recognize phosphatidylserine on dying cells. Instead, several bridging molecules have been identified that recognize this and other eat me signals. The best characterized of these molecules are the soluble protein MFGE8 (rEfS 88, 122) and the glycolipid-anchored protein T cell immunoglobulin domain and mucin domain protein 4 (TIM4) 89 . Evidence also supports roles for annexin I 123 and growth arrest specific 6 (GAS6) 124 in the recognition of phosphatidylserine exposed on dying cells. Other bridging molecules include thrombospondin, complement component 1q (C1q) and apolipoprotein H. The receptors for these bridging molecules that are expressed by phagocytes include αvβ3 integrin and αvβ5 integrin (which bind MFGE8 and thrombospondin), the MER protein tyrosine kinase family (which binds GAS6), the scavenger receptors CD36 and steroid receptor activator 1 (which bind oxidized lipids), and the C1q receptors CD91 and calreticulin. Calreticulin is also expressed by dying cells. antigen, which inhibited the induction of a cell-mediated immune response (that is, they mediated tolerance). Thus, exposure to apoptotic cells shifts the system from the classical 'helped' CTl-mediated immune responses to those induced by tolerogenic, helpless CTls that produce TRAIl following re-exposure to antigen. In support of this, TRAIl-deficient mice were resistant to the induction of tolerance mediated by the intravenous injection of apoptotic cells 73 . These considerations have led us to propose the following scenario (fIG. 2) . After the injection of apoptotic cells, the associated antigen is presented to CD8 + CTls in the absence of CD4 + T cell help. The helpless CTls function as primary effector cells and therefore seem to be fully functional CTls 25, 26, 68 . However, following re-exposure to antigen, the helpless CTls release TRAIl, resulting in their deletion and the suppression of further CD4 + T cell-mediated responses, and therefore the induction of tolerance. Nevertheless, studies exploring the function of CTls following their exposure to apoptotic cells have yet to formally test this hypothesis.
Nature Reviews | Immunology

Location of dying cells and those that engulf them.
In several mouse models of contact hypersensitivity and delayed-type hypersensitivity, antigen-coupled cells injected intravenously induce a state of immune tolerance to the antigen 18, 19 through a process that involves apoptosis of the injected cells 11 . However, it has long been known that subcutaneous injection of the same cells results in the activation of an immune response 74, 75 , and most studies of immunogenic apoptosis involve injection by this route. Subcutaneous injection of cells leads to their engulfment by skin-derived DCs that ultimately traffic to the lymph nodes and mediate an immune response. This may mimic the effect of tumours that are implanted into subcutaneous sites and that undergo apoptosis following chemotherapy 76, 77 . By contrast, intravenous injection of apoptotic cells leads to their localization in the spleen, which is known to be crucial for the induction of tolerance following the intravenous injection of antigens. For example, splenectomy abolishes tolerance that is induced by the intravenous injection of hapten-modified spleen cells 18 or by the injection of hapten-modified spleen cells or viruses into the anterior chamber of the eye 10, 78 . Thus, it seems that the spleen, and not the lymph nodes, is the organ where tolerance was induced in these settings.
localization of apoptotic cells to the spleen could influence the type of DC that engulfs the dying cells, which could affect whether tolerance or an immune response are induced, as several observations suggest that distinct DC subsets in the spleen show different
Reactive oxygen species
Oxygen radicals that are produced by the mitochondrial respiratory chain and by other processes. When found in excessive quantities, they can cause intracellular and mitochondrial damage, which promotes cell death.
responses to stimuli from dead cells 79, 80 . Indeed, splenic CD8α + DCs are potent inducers of tolerance, whereas splenic CD8α -DCs promote immune responses 11, 81 . In addition, CD8α + DCs were shown to preferentially phagocytose apoptotic cells 81 . It is also noteworthy that there seems to be a difference in antigen processing and presentation that is intrinsic to these DC subsets: CD8α + DCs tend to process antigens predominantly for presentation by MHC class I molecules, whereas CD8α -DCs also present antigens on MHC class II molecules 80 . This suggests that the preferential induction of tolerance by CD8α + DCs might induce diminished CD4 + T cell-mediated but enhanced CD8 + T cell-mediated immune responses, resulting in helpless CTl induction as discussed above.
However, exceptions should be noted. Bone marrowderived myeloid DCs (which are predominantly CD8α -) that engulf apoptotic cells in vitro are effective at inducing tolerance when injected intravenously 11, 51, 73 . In addition, CD8α + DCs in the skin are potent inducers of antiviral immunity 82 and not tolerance. These observations would suggest that it may be the location of the uptake of dying cells rather than the type of DC that dictates the outcome. For example, following intravenous injection of DCs that have engulfed apoptotic cells, the DCs were shown to traffic to the marginal zones of the spleen, where they induced immune tolerance; by contrast, subcutaneous injection of these same DCs resulted in the induction of an immune response 11 . Interestingly, the spleen is not the only location that seems to be involved in tolerance induction by dying cells; lymphoid cells that die in vivo tend to accumulate in the liver 83 , and this organ has also been implicated in tolerance induction 84 . The uptake of apoptotic cells by DCs can have several consequences that can affect the immune response. It is widely thought that DC maturation, as measured by the increased expression of MHC class II and co-stimulation molecules (such as CD80 and CD86) is crucial for the induction of an immune response 15 , whereas immature DCs induce immune tolerance 17, 26 . One consequence of the engulfment of apoptotic cells is that it can prevent DC maturation in some cases 85 , which would result in the induction of tolerance. This is a compelling idea that partially explains the ability of apoptotic cells to induce tolerance, especially in conjunction with the effect of helpless CTls discussed above. However, it should be noted that there are several reports showing that mature DCs can induce tolerance following engulfment of apoptotic cells 11, 51, 73 , and indeed DC maturation can be required for tolerance induction under certain circumstances 15 . Thus, the maturation state of the DC cannot be the sole determining factor for tolerance induction, and the DC type and tissue localization, as discussed above, are probably also important.
Receptors for dying cells. Receptors involved in the recognition and/or engulfment of apoptotic cells (BOX 4) can determine the outcome of the immune response to dying cells. Some patients with systemic lupus erythematosus have defects in the engulfment of apoptotic cells 4, 86 , although the cause (and generality) of such defects remain unresolved. Genetic deletion or neutralization of some molecules involved in the engulfment of dying cells, such as the receptor tyrosine kinase MeR (also known as MeRTK), MFGe8 (milk fat globule eGF factor 8 protein), TIM4 (T cell immunoglobulin domain and mucin domain protein 4) or C1q (complement component 1q), can compromise the induction of self tolerance and result in systemic autoimmune disease [87] [88] [89] . However, this is not the case for other molecules that are involved in engulfment. Disruption or blockade of CD14, CD26, β3 integrin, β5 integrin or mannose-binding lectin, all of which are associated with the uptake of dying cells (BOX 4) , leads to the accumulation of apoptotic bodies but does not result in autoimmunity 90 . This indicates that it is not a defect in the engulfment of apoptotic cells per se that causes the autoimmune disease. Interestingly, similarly to wild-type macrophages, macrophages from mice that lack CD26, β3 integrin or β5 integrin secrete the immunosuppressive cytokine transforming growth factor-β (TGFβ; see below) in response to apoptotic cells 91 , and this may help to explain why these mice fail to clear apoptotic bodies but do not develop autoimmunity.
Modification of DAMPs. All cells that die can release
DAMPs, but the process of apoptosis can modify these immunostimulatory molecules to promote tolerance instead of an immune response. Necrotic cells were shown to promote antigen-specific immune responses through a mechanism that involved the release of HMGB1 when the cells were injected intravenously; in the absence of active HMGB1, these cells induced tolerance 51 . Similarly, apoptotic cells can induce an immune response rather than tolerance if caspase activation is blocked or if apoptotic cells that lack the expression of caspase 3 and caspase 7 are engulfed by DCs. This seems to contradict the requirement for caspase activation in immunogenic cell death (discussed above), but again, perhaps factors such as the location of the dying cells may have an effect. In addition, it is clear that events which take place during apoptosis can modify the immune response. This would include the production of reactive oxygen species (ROS) and the release of immunosuppressive molecules from dying cells.
Perhaps the best example of this is related to the production of ROS as a consequence of caspase activation 11, 51, 73 . During apoptosis, mitochondria permeabilize to release cytochrome c, which in turn activates caspases. Caspases then cleave a component of complex I in the electron transport chain NDuFS1 (NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa) in the permeabilized mitochondria 92 . The resulting inhibition of complex I function induces the production of ROS, which oxidizes a key cysteine residue in HMGB1, neutralizing its ability to promote immune responses 51 . Mutation of the caspase cleavage site in NDuFS1 does not block apoptosis, but apoptotic cells that express this mutant protein promote immune responses rather than tolerance despite releasing HMGB1 following secondary necrosis
. Therefore, caspase activation during apoptosis promotes the generation of ROS, which compromises the immunostimulatory activity of HMGB1, thereby leading to tolerance. Thus, one important factor in determining whether tolerance or an immune response will ensue is whether dying cells can modify HMGB1 and perhaps other DAMPs during apoptosis. One prediction would be that during immunogenic cell death (such as might occur following some types of chemotherapy) ROS is not produced and DAMPs remain unmodified. However, this hypothesis remains to be tested. In addition, the effects of ROS production on immune outcome during some forms of necrotic cell death have not yet been explored.
Release of immunosuppressive mediators.
Another mechanism that has been proposed to explain the tolerogenic effects of apoptotic cells is the release of immunosuppressive cytokines from either the dying cell or the cell that engulfs it. When in contact with macrophages, apoptotic cells induce the secretion of anti-inflammatory cytokines such as TGFβ, Il-10, platelet-activating factor and prostaglandin e 2 (rEfS [93] [94] [95] . Apoptotic cells also stimulate the production of lipid mediators such as 15-lipoxygenase and 15-hydroxyeicosatetraenoic acid, which can participate in the resolution of inflammation 96 . A role for TGFβ has been shown in a model of lung inflammation in which the administration of apoptotic cells inhibits the inflammatory response 97 . In another system, the induction of extensive apoptosis following infection by intracellular trypanosomes promoted the production of TGFβ, which inhibited macrophage responses, thereby allowing the survival of the pathogen 98 . Thus, the interaction of apoptotic cells with macrophages can induce the production of inhibitory cytokines that restrict immune responses by the macrophages. This effect may simply involve the recognition of eat me signals on the apoptotic cells by the macrophages, as the administration of vesicles containing phosphatidylserine (which mimic the eat me signal) was shown to inhibit adaptive immune responses in a TGFβ-dependent manner 99 . In addition to the production of TGFβ by macrophages, apoptotic cells can also produce immunosuppressive cytokines such as Il-10 (rEf. 100) and TGFβ 101 as they die, which can influence the type of antigen-specific T cell response that is induced. Apoptotic T cells released bioactive TGFβ in the absence of Tgfb transcription. Indeed, TGFβ was shown to be localized in an intracellular membrane-bound compartment for release into the cytoplasm following loss of mitochondrial membrane potential. The release of TGFβ from apoptotic T cells inhibited the production of pro-inflammatory cytokines by activated macrophages, resulting in immune suppression 101 . These observations highlight that TGFβ secretion can influence the ways in which apoptotic cells might affect the immune system. The production of TGFβ by macrophages or DCs that have engulfed apoptotic cells can promote the generation of inducible regulatory T (T Reg ) cells, and administration of apoptotic cells has been shown to generate inducible T Reg cells in some settings 102, 103 . Such inducible T Reg cells can contribute to the tolerogenic effects of apoptotic cells on the immune system. However, the situation can be more complex: if Il-6 is also present, for example, owing to TlR engagement or other inflammatory signals, apoptotic cells can drive the generation of inflammatory T helper 17 cells rather than T Reg cells, a phenomenon that has recently been shown to occur when apoptosis is induced by bacterial infection 104 .
Conclusions
The mechanisms our immune system uses to deal with dead and dying cells are complex. understanding (and possibly manipulating) these processes can have important implications for the study of cancer biology, infectious diseases, tissue injury and autoimmunity. Dead cells are handled differently by the immune system depending on several factors that are related to the type of cell death, the cell death pathway, how the dead cells are engulfed, the engulfing cell, where the engulfment takes place and which cells of the immune system eventually encounter the antigens presented along with the dead cells. All of these issues must be considered when trying to make predictions concerning the impact of cell death on the immune system.
Although the process of cell death can modify antigens that are associated with the dying cell, we suspect that it is the effects of DAMPs and other mediators that dictate the effect of cell death on DCs and the immune response. This is not simply because of the presence or absence of co-stimulatory signals or the maturation status of the DC that engulfs the dying cell, but seems to include other signals that have not yet been elucidated. It is probable, however, that the source of intact or altered self antigens from dying cells serves to sustain self tolerance under normal conditions and can trigger autoimmune responses when the process goes awry.
But, why are the effects of dying cells on the immune system so complex? Perhaps this is the price we are paying for our highly evolved immune systems. We know that a failure or delay of removing dying cells can have autoimmune consequences, but the mechanisms of their removal are highly conserved in animals that have no adaptive immune system and do not show anything resembling an inflammatory response if the dead cells are not removed. When the complexity of the vertebrate immune system was increased to deal with pathogens, it also increased the chances of eliciting autoimmune reactions. As our immune system evolved, pathogens evolved parallel ways to avoid detection, exploiting this newfound complexity 105 . Therefore, it is plausible that the immune response to dead and dying cells was a recent add-on to the complex and conserved processes of cell death and removal. If dying cells provide the antigens that sustain peripheral tolerance, then parasites that trigger cell death would be tolerated by the immune system, which is clearly untenable. The alternative theory -that dying cells are always immunogenic -is equally flawed, as the potential for autoimmunity would be extremely high. The immune system seems to evaluate cell death according to several criteria to try to stay one step ahead. like the Red Queen in Alice in Wonderland, it takes all the "running" our evolving immune system can do to "stay in the same place" with respect to the consequences of dying cells for the immune response.
